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Abstract
Summary The aim was to meta-analyze randomized con-
trolled trials of calcium plus vitamin D supplementation and
fracture prevention. Meta-analysis showed a significant 15 %
reduced risk of total fractures (summary relative risk estimate
[SRRE], 0.85; 95 % confidence interval [CI], 0.73–0.98) and
a 30 % reduced risk of hip fractures (SRRE, 0.70; 95 % CI,
0.56–0.87).
Introduction Calcium plus vitamin D supplementation has
been widely recommended to prevent osteoporosis and sub-
sequent fractures; however, considerable controversy exists
regarding the association of such supplementation and frac-
ture risk. The aim was to conduct a meta-analysis of random-
ized controlled trials [RCTs] of calcium plus vitamin D sup-
plementation and fracture prevention in adults.
Methods A PubMed literature search was conducted for the
period from July 1, 2011 through July 31, 2015. RCTs
reporting the effect of calcium plus vitamin D supplementa-
tion on fracture incidence were selected from English-
language studies. Qualitative and quantitative information
was extracted; random-effects meta-analyses were conducted
to generate summary relative risk estimates (SRREs) for total
and hip fractures. Statistical heterogeneity was assessed using
Cochran’s Q test and the I2 statistic, and potential for publica-
tion bias was assessed.
Results Of the citations retrieved, eight studies including 30,
970 participants met criteria for inclusion in the primary anal-
ysis, reporting 195 hip fractures and 2231 total fractures.
Meta-analysis of all studies showed that calcium plus vitamin
D supplementation produced a statistically significant 15 %
reduced risk of total fractures (SRRE, 0.85; 95 % confidence
interval [CI], 0.73–0.98) and a 30 % reduced risk of hip frac-
tures (SRRE, 0.70; 95%CI, 0.56–0.87). Numerous sensitivity
and subgroup analyses produced similar summary associa-
tions. A limitation is that this study utilized data from sub-
group analysis of the Women’s Health Initiative.
Conclusions This meta-analysis of RCTs supports the use of
calcium plus vitamin D supplements as an intervention for
fracture risk reduction in both community-dwelling and insti-
tutionalized middle-aged to older adults.
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Introduction
The risk of osteoporotic fractures increases with age among
individuals aged >50 years [1, 2]. Although many factors
contribute to this debilitating event, the most significant
causes are reduction in bone mass, structural deterioration,
and increased frequency of falls. Calcium plus vitamin D sup-
plementation has been widely recommended for the preven-
tion of osteoporosis and subsequent fractures; however, recent
data have been inconsistent. Whereas some studies show that
calcium plus vitamin D supplementation reduces the risk of
fractures, others show no effect, and one study shows that
supplementation may increase the risk. Concern has arisen
recently that calcium supplementation may be harmful, so
some individuals and healthcare providers are reluctant to
use calcium supplements [3]. On the other hand, there is a
growing interest in the role of vitamin D to support bone
health, and healthcare providers are increasing their use of
laboratory tests to assess vitamin D status among the
population.
In 2007, the USAgency for Healthcare Research and Qual-
ity (AHRQ) University of Ottawa Evidence-based Practice
Center (EPC) published an evidence synthesis on the effec-
tiveness and safety of vitamin D in relation to bone health [4].
This synthesis suggested that there was fair evidence of an
association between circulating 25-hydroxyvitamin D concen-
trations, the functional indicator of vitamin D status, with
some bone health outcomes (e.g., bone mineral density); how-
ever, this evidence was inconsistent across populations includ-
ing infants and children [4]. The AHRQ Tufts University EPC
subsequently published two additional evidence-based reports
on this topic. The first evidence report, published in 2009 [5],
was conducted to support the development of dietary refer-
ence intakes for calcium and vitamin D from the Institute of
Medicine [6]. The second evidence report, published in 2011
[7], was conducted to support recommendations from the US
Preventive Services Task Force (USPSTF) for use of vitamin
D (with or without calcium) for prevention of cancer and
fractures [8]. The 2011 Tufts EPC evidence report [7] included
a meta-analysis that was weighted heavily by a nonsignificant
effect of calcium plus vitamin D in preventing hip fracture
from the Women’s Health Initiative (WHI) due to its large
sample size (36,282 postmenopausal women) [9]. Based on
the findings from the 2011 Tufts EPC evidence report [7], as
well as other evidence available at that time, the USPSTF
recommended against daily supplementation with ≤400 IU
vitamin D3 and ≤1000 mg calcium or supplemental vitamin
D alone for the primary prevention of fractures in noninstitu-
tionalized postmenopausal women [8]. However, additional
data on the topic have now been published, including new
information from the WHI that incorporated both adherence
and personal use of supplements at baseline [10]. As a result,
the National Osteoporosis Foundation convened an expert
panel to provide an updated review of the evidence linking
calcium plus vitamin D to fracture prevention that expands the
data considered in the 2011 Tufts EPC evidence report [7]
with these newer data.
Methods
Literature search and study inclusion
Two comprehensive literature searches were conducted. First,
a PubMed andMedline literature search was conducted for the
period from July 1, 2011 through July 31, 2015, to update the
meta-analysis of randomized controlled trials (RCTs) present-
ed in the Tufts EPC evidence report [7]. The following med-
ical subject headings (MeSH) were used: vitamin D, calcium,
bone fractures, accidental falls, bone density, and clinical tri-
als. In addition, free-text terms and relevant variants for vita-
min D, calcium, fractures, accidental falls, bone density, and
clinical trials were used in the search. We included RCTs of
generally healthy adults (<20 % of study participants had ma-
jor chronic diseases such as diabetes or cardiovascular disease,
at baseline) that compared vitamin D supplementation plus
calcium against no supplementation or placebo. We excluded
studies that enrolled pregnant women only or measured vita-
min D status only during pregnancy and RCTs comparing
different dosages of vitamin D supplementation without a
control group that did not receive vitamin D supplementation.
To include available data on elderly persons (aged ≥65 years),
we also accepted RCTs of older ambulatory adults with any
disease other than cancer. We excluded short-term (<1 month)
RCTs and trials that used synthetic vitamin D analogs (for
example, oxacalcitriol or paricalcitol). Fracture outcomes in-
cluded total and hip fractures. All articles were screened by
title, abstract, and, in some cases, full-text review. A complete
manual search of reference lists of original studies was con-
ducted. A total of 582 abstracts were identified that
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incorporated vitamin D plus calcium search strings (Fig. 1).
This search identified the WHI analysis published by Prentice
et al. [10] and the 2011 Tufts EPC evidence report [7], which
supported the effectiveness of the literature search strategy.
Based on the title and abstract review, 24 studies were consid-
ered potentially eligible and were retrieved for full-text screen-
ing [10–33], plus 11 originally included studies from the Tufts
EPC report [9, 34–43]. Additionally, we identified a correc-
tion to the 2011 Tufts EPC evidence report, which was pub-
lished in the October 2014 edition of the Annals of Internal
Medicine [44]. This letter indicated that three originally in-
cluded studies compared calcium plus vitamin D supplemen-
tation with a calcium supplement placebo. These three studies
[37, 40, 41] along with one additional study [28] reviewed in
the full-text screening were excluded since they did not com-
pare calcium plus vitamin D supplementation with a placebo.
Fourteen remaining studies were excluded since they did not
directly evaluate the effect of calcium with combined vitamin
D supplementation on fracture prevention [11, 14–16, 18, 19,
21, 22, 25, 27, 30–33]. Eight additional studies were excluded
because of non-RCT study design [12, 20, 23], article not in
English [24], hospitalized population [26], and repeated data
sources fromWomen’s Health Initiative [13, 17, 29]. Thus, the
study by Prentice et al. [10] was the only remaining study that
met the specified inclusion criteria in the updated search.
In addition to replicating and augmenting the 2011 Tufts
EPC evidence report’s literature search [7] as described above,
we conducted a second comprehensive search of all available
literature without limits by year of publication. No additional
studies were identified (2329 citations were identified after
deduplication).
Data extraction
We extracted qualitative and quantitative information from
each study, including author and year of study, geographic
study location, name of the trial (if applicable), trial size, du-
ration of follow-up, type of exposure, exposure metric units,
analytical comparisons, number of fracture events, and rela-
tive risks (RRs) with 95 % confidence intervals (CIs). The
2011 Tufts EPC evidence report [7] calculated RRs based on
the number of events and group size in each individual study.
For our analyses, we extracted the calculated RR and CI data
if available in the individual study, and we calculated RRs and
CIs from event and group size data in the absence of reported
RR estimates. By utilizing this methodology, we were able to
obtain the most accurate RR based on multivariate statistical
analyses. The largest source of data on this topic originates
from the WHI calcium plus vitamin D supplementation clin-
ical trial, for which 36,282 postmenopausal women were en-
rolled. In 2006, Jackson et al. [9] published an analysis of
calcium plus vitamin D supplementation and the risk of frac-
tures among participants in this trial. The results from this
analysis were included in the 2011 Tufts EPC evidence report
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[7]. Since this publication, Prentice et al. [10] conducted an
updated and more comprehensive post hoc analysis of the
WHI clinical trial and published the results in 2013. The authors
reported total and hip fracture risk estimates for calcium plus
vitamin D supplementation in all participants, as well as those
adherent participants who did not use self-selected Bpersonal^
(i.e., not provided by the study) calcium with or without com-
bined vitamin D supplements at baseline. In addition, Prentice
et al. [10] reported data at baseline as well as for the duration of
supplementation throughout the study. Thus, data from the
study by Prentice et al. [10] replaced data from the study by
Jackson et al. [9] in a subanalysis presented herein (Table 1).
Statistical analyses
Random-effects models were used to calculate summary rel-
ative risk estimates (SRREs), 95 % CIs, and corresponding P
values for heterogeneity. Meta-analysis models were generat-
ed to examine the RR of vitamin D plus calcium supplemen-
tation on total and hip fractures. Subgroup and sensitivity
analyses were performed to examine summary effects based
on certain study characteristics such as the use of personal
supplements, adherence to assigned study pills (1000 mg cal-
cium carbonate plus 400 IU vitamin D3 per day) in the WHI,
and institutionalized versus community-dwelling individuals.
Prior to conducting new subanalyses, we replicated the
meta-analysis presented in the published erratum [44], which
used the previous WHI data from Jackson et al. [9]. After
successful replication, we generated a subanalysis using the
updated WHI data as reported by Prentice et al. [10]. Pren-
tice et al. [10] report hazard ratios and 95 % CIs for total
and hip fracture for all trial participants with and without
personal supplement use (see Table 2 in Prentice et al.
[10]), and for trial participants who adhered to their assigned
study pills with and without personal supplement use (see
Table 6 in Prentice et al. [10]). For our subanalysis, we used
data among trial participants in the WHI who did not use
personal supplements and who adhered to their assigned
pills as our base case. We were not able to look at personal
supplement use and adherence among other trials included
in the meta-analysis, since these data are not currently avail-
able in the peer-reviewed literature. Sensitivity analyses
were conducted for all combinations of data reported by
Prentice et al. [10]. As indicated previously, our primary
outcome analysis was the comparison of calcium plus vita-
min D supplementation versus a placebo.
One-study-removed influence analyses were conducted to
determine the relative influence (i.e., weight) of each study on
the overall risk estimate. Statistical heterogeneity was assessed
using Cochran’s Q test and the I2 statistic. The presence of
publication bias was assessed visually by examining a funnel
plot measuring the standard error as a function of effect size, as
well as by performing Egger’s regression method and the
Duval and Tweedie imputationmethod [45]. All statistical anal-
yses were performed using Comprehensive Meta-Analysis
software (version 2.2046; Biostat Inc., Englewood, NJ).
Table 1 Summary of meta-analysis results for calcium plus vitamin D supplementation versus placebo and fracture risk
Reference Status Vitamin D
(IU/day)
Calcium
(mg/day)
No. of total fracture events/total No. of hip fracture events/total
RR (95 % CI) Treatment Control RR (95 % CI) Treatment Control
Chapuy
et al. [20]
Institutionalized 800 1200 0.74 (0.56–0.97) 80/1387 110/1403 0.74 (0.56–0.97) 21/1387 37/1403
Chapuy
et al. [21]
Institutionalized 800 1200 0.62 (0.36–1.07) 27/393 21/190 0.62 (0.36–1.07) 27/393 21/190
Dawson-Hughes
et al. [22]
Community-dwelling 700 500 0.46 (0.23–0.90) 11/187 26/202 0.36 (0.01–8.77) 0/187 1/202
Porthouse
et al. [23]
Community-dwelling 800 1000 1.01 (0.71–1.43) 58/1321 91/1993 0.75 (0.31–1.80) 8/1321 17/1993
Prentice
et al. [10]a
Community-dwelling 400 1000 0.90 (0.78–1.03) 405/7530b 458/7801b 0.55 (0.32–0.97) 19/7530b 35/7406b
Salovaara
et al. [24]
Community-dwelling 800 1000 0.83 (0.61–1.12) 78/1586 94/1609 2.02 (0.37–11.02) 4/1586 2/1609
Grant et al. [25] Community-dwelling
with history of
fracture
800 1000 1.02 (0.89–1.16) 387/2649 377/2643 ND ND ND
Harwood
et al. [26]
Community-dwelling
with history of
fracture
800 1000 0.57 (0.15–2.19) 3/39 5/37 ND ND ND
CI confidence interval, ND no data, RR relative risk, WHIWomen’s Health Initiative
a Data analyzing the WHI for adherence to assigned pills and no personal use of supplements from Table 6 in Prentice et al. [10]
b Data provided from WHI investigators
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Results
We successfully reproduced the findings of Chung et al. [44]
in regard to total fractures and hip fractures, as presented in the
recently published erratum. Our subanalyses contained a total
of eight RCTs [10, 34–36, 38, 39, 42, 43] assessing the effect
of calcium plus vitamin D supplementation versus placebo on
total fracture incidence and six RCTs [10, 34–36, 42, 43]
assessing the effect of calcium plus vitamin D supplementa-
tion versus placebo on hip fracture incidence (Figs. 2 and 3). A
total of 195 hip fracture events and 2231 total fracture events
based on 30,970 participants analyzed across all studies were
evaluated meta-analytically for the subanalyses on total frac-
tures (Fig. 2) and hip fractures (Fig. 3). Follow-up in the trials
ranged from approximately 1 to 7 years. Two studies analyzed
participants in an institutionalized study setting, whereas six
studies analyzed community-dwelling participants. The calci-
um dosages ranged from 500 mg/day in one study to 1000–
1200 mg/day in the remaining studies. Six studies provided
800 IU/day vitamin D, whereas dose levels were 400 and
700 IU/day in the remaining two studies.
As mentioned above, before conducting these de novo me-
ta-analyses, we replicated the findings from the Tufts EPC
evidence report corrected erratum (SRRE comparing calcium
plus vitamin D and total fracture versus placebo, 0.91; 95 %
CI, 0.81–1.01) [44]. The SRRE of this analysis changed
slightly (SRRE, 0.89; 95 % CI, 0.79–1.01) after making some
analytical modifications and using multivariate RRs extracted
directly from some studies. In the current meta-analyses, we
replaced the WHI data from Jackson et al. [9] with updated
data from Prentice et al. [10]. Meta-analysis of calcium plus
vitamin D supplementation (versus placebo) using the
subanalysis by Prentice et al. [10] resulted in a statistically
significant 14 % reduction in total fractures (SRRE, 0.85;
95 % CI, 0.73–0.98; using data for adherence to assigned pills
and no personal supplements from Table 6 in Prentice et al.
[10]) (Fig. 2a).
Visual inspection of the funnel plot for the overall model of
calcium plus vitamin D supplementation and total fracture
indicated slight publication bias (Fig. 2b), and the Egger’s
regression test produced a statistically significant P value
(0.04). However, this publication bias assessment was skewed
because the WHI clinical trial published by Prentice et al. [10]
and the Randomised Evaluation of Calcium or Vitamin D
clinical trial published by Grant et al. [38] were considerably
larger than all of the other studies in the model—contributing
approximately 50 % of the relative weight. Despite this, the
SRREs ranged between 0.82 and 0.90 after removal of each
individual study in our one-study-removed influence analysis.
In a sensitivity analysis, removing the studies by Prentice et al.
[10] and Grant et al. [38] simultaneously resulted in an SRRE
of 0.77 (95 % CI, 0.63–0.94) with a P value for heterogeneity
of 0.256. Collectively, two individual studies reported null
associations between calcium plus vitamin D supplementation
and total fracture, whereas the remaining studies observed
decreased risks of fracture (two of these associations were
Fig. 2 Calcium plus vitamin D
supplementation versus placebo
and total fracture. aMeta-analysis
of eight RCTs. b Funnel plot of
standard error by log rate ratio for
calcium plus vitamin D
supplementation and risk of total
fracture. aBased on data from
Table 6 in Prentice et al. [10]
regarding adherence to study pills
and no personal supplements. CI
confidence interval, SSRE
summary relative risk estimate
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statistically significant). Meta-analysis of the six studies of
total fracture involving community-dwelling participants
[10, 36, 38, 39, 42, 43] resulted in an SRRE of 0.95 (95 %
CI, 0.85–1.06), whereas the SRRE for the two studies among
institutionalized participants [34, 35] was 0.67 (95 % CI,
0.52–0.88).
We conducted sensitivity analyses for total fracture using
all data sources from the WHI trial; however, summary asso-
ciations were modified only slightly. When data for adherence
to assigned pills (personal supplements included; Table 6 in
Prentice et al. [10]) were used, the SRRE for calcium plus
vitamin D supplementation (versus placebo) was 0.87 (95 %
CI, 0.76–1.00). When overall data for calcium plus vitamin D
supplementation (versus placebo) were used (Table 2 in Pren-
tice et al. [10]), the summary associations were 0.88 (95 % CI,
0.77–1.00) and 0.87 (95 % CI, 0.76–1.00) for all study partic-
ipants and for study participants with no personal supplement
use, respectively.
Calcium plus vitamin D supplementation (versus placebo)
resulted in a statistically significant 30 % decreased risk of hip
fractures based on meta-analysis of six trials (SRRE, 0.70;
95 % CI, 0.56–0.87) (Fig. 3a). The individual study RRs
ranged between 0.36 and 0.75, except for the outlier study
by Salovaara et al. [43], for which an RR of 2.02 was reported
(Fig. 3a). However, this study provided very little relative
weight to the overall model, and its removal did not alter the
overall effect size. As with the findings for total fracture, sta-
tistically significant reductions in hip fracture risk remained
when data for adherence to assigned pills only (Table 6 in
Prentice et al. [10]), no personal supplements only (Table 2
in Prentice et al. [10]), and all groups combined (Table 2 in
Prentice et al. [10]) were analyzed. A borderline statistically
significant 38 % reduction in hip fracture risk was observed in
the meta-analysis of four studies involving community-
dwelling participants [10, 36, 42, 43] (SRRE, 0.65; 95 % CI,
0.41–1.01). Only two studies reported hip fracture events
among institutionalized participants [34, 35], but the risk re-
duction was significant (SRRE, 0.71; 95%CI, 0.56–0.91). No
evidence of publication bias was apparent after inspection of
the funnel plot for hip fracture (Fig. 3b) and based on Egger’s
regression test (P=0.901). Furthermore, all meta-analysis
models for hip fracture were homogeneous, and results were
consistent within and between models. Statistical significance
remained after our one-study-removed influence analysis with
SRREs ranging between 0.64 and 0.73, indicating the statis-
tical robustness of calcium plus vitamin D supplementation on
hip fracture prevention.
Discussion
Our meta-analysis substituting the study by Jackson et al. [9]
with the subanalysis by Prentice et al. [10] showed statistically
significant reductions in risk for both total and hip fractures,
which supports the use of calcium plus vitamin D supplemen-
tation to reduce fracture risk. Identification of strategies to
reduce fracture risk is important, given that osteoporosis and
low bone mass affected an estimated 53.6 million Americans
aged >50 years in 2010 [46]. Over two million osteoporosis-
related fractures occur each year in the United States,
Fig. 3 Calcium plus vitamin D
supplementation versus placebo
and hip fracture. aMeta-analysis
of six RCTs. b Funnel plot of
standard error by log rate ratio for
calcium plus vitamin D
supplementation and risk of hip
fracture. aBased on data from
Table 6 in Prentice et al. [10]
regarding adherence to study pills
and no personal supplements. CI
confidence interval, SSRE
summary relative risk estimate
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accounting for >$19 billion in annual healthcare costs [47].
National surveys show that many Americans do not consume
recommended amounts of calcium and vitamin D [48, 49].
Both nutrients are important for optimal skeletal health across
the lifecycle: calcium is the dominant mineral in bone, and
vitamin D is important for the efficient absorption of calcium
and for effective functioning of bone cells.
Our meta-analysis differs from the 2011 Tufts EPC evi-
dence report [7] and corrected erratum [44] in several ways.
One important difference is our use of the data from the WHI
published by Prentice et al. [10], which focused on a subset of
participants in the WHI randomized clinical trial who did not
use personal supplements at baseline and who were adherent
to study pills. By contrast, the Tufts EPC evidence report [7]
and corrected erratum [44] included WHI results from all
women in the randomized clinical trial arm of the WHI that
was designed to assess calcium plus vitamin D supplementa-
tion without regard to personal supplement use or adherence
to study pills [9]. The differences in these two meta-analyses
may partially explain the difference in findings between the
two WHI analyses. For example, Prentice et al. [10] found a
significant reduction in fracture risk associated with the use of
calcium plus vitamin D supplements, whereas Jackson et al.
[9] found that supplementation did not reduce hip fracture
incidence in the overall cohort (subcohort analysis of adherent
individuals showed a significant effect on hip fracture reduc-
tion). There are strengths associated with including the results
of Prentice et al. [10] rather than the results of Jackson et al.
[9]. Specifically, Prentice et al. [10] focused on those individ-
uals who took the supplements. In addition, their study design
also improved the ability to assess the effect of a threshold
nutrient such as calcium, because efficacy of interventions for
threshold nutrients cannot be established in individuals who
are already sufficient [50]. Thus, we concluded that the results
of Prentice et al. [10] were more appropriate because they
considered adherent participants who were not already taking
supplements at baseline. However, per-protocol analysis is a
concern because subanalysis jeopardizes the assumptions of
randomization. Some would argue that we have no trial data
with high enough retention rates in individuals who were suf-
ficiently compliant with treatment to have the needed evi-
dence to make conclusions about calcium plus vitamin D sup-
plementation [51]. However, treatments cannot work if they
are not taken. Thus, the study by Prentice et al. [10], which
considers adherent participants who were not already taking
supplements at baseline, is what the authors of the present
study consider to be the most nutritionally relevant evidence
from the WHI available at this time. Our study is further lim-
ited by the lack of published data on the number of subjects
taking personal supplements at baseline and/or adherence
among participants in other trials included in the analyses.
For example, based on questionnaire responses collected at
24 months during the RECORD trial, only 2886 (54.5 %) of
the 5292 participants were still taking tablets (8.5 % had died,
1.1 % had withdrawn, and 35.8 % had stopped taking tablets
but were still providing data on at least the main outcomes)
[38].
In addition, we extracted multivariate RR data if reported in
the individual study, rather than calculate a crude RR based on
the number of events and total participants. We did not gener-
ate models or conduct analyses based on a study quality as-
sessment. Rather, we conducted one-study-removed sensitiv-
ity analyses to determine the relative impact of each study on
the overall model and found summary effects that did not
deviate from the overall effect size, indicating the robustness
of the analyses. This is important when assessing generaliz-
ability of the findings on various population groups such as
the two studies [38, 39] of individuals with a history of frac-
ture. There was some evidence of publication bias for total
fracture results, but summary associations remained statisti-
cally significant after removal of each individual study in our
influence analysis, which suggests that the impact of this pub-
lication bias was not large.
Other recent meta-analyses have found null effects of vita-
min D supplementation alone on fracture outcomes [7, 52,
53]. Although vitamin D is used to support bone health, the
current evidence for an effect of supplemental vitamin D alone
on fracture outcomes is limited and conflicting. Large-scale,
randomized controlled studies testing whether supplemental
vitamin D versus placebo has effects on fracture outcomes are
needed and are currently underway. The Vitamin D and
Omega-3 Trial (VITAL), in studies sponsored by the National
Institutes of Health, is currently testing the effects of supple-
mental 2000 IU vitamin D (cholecalciferol) on fracture out-
comes among 25,875 women and men across the United
States [54].
It is well known that vitamin D promotes calcium absorp-
tion in the gut and helps to maintain adequate serum calcium
concentrations to enable normal mineralization of the bone.
Vitamin D is needed for bone growth and bone remodeling by
osteoblasts and osteoclasts. Thus, calcium and vitamin D
work together synergistically on the bone, and the results of
our meta-analysis support their combined use to reduce frac-
ture risk. Furthermore, the dosage of vitamin D administered
in the WHI (400 IU/day) may not have been high enough to
adequately influence fracture outcomes. This might also par-
tially explain the null findings reported in previous meta-
analyses of calcium plus vitamin D supplementation, given
the relatively large influence of the WHI on results in these
meta-analyses. The dose of vitamin D administered in the
WHI was lower than any other RCT included in this updated
meta-analysis.
In conclusion, combined calcium plus vitamin D supple-
mentation is statistically significantly associated with reduced
total and hip fractures across various populations. Collective-
ly, decreased risks for hip fractures were stronger in
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magnitude, and results were more homogeneous compared
with total fractures, but consistent decreased risks were ob-
served for both fracture outcomes. Our analyses indicate that
supplementation could decrease the risk of total and hip frac-
tures by 15 and 30 %, respectively, which could decrease the
public health burden of osteoporotic fractures. Our meta-
analysis updates and expands the current state of the science
on this public health issue and clinically important topic area.
Additional clinical RCTs that address personal use of supple-
ments and adherence to allocated interventions may better
facilitate our understanding of the role of supplemental calci-
um plus vitamin D and vitamin D alone on fracture preven-
tion. The findings from this quantitative assessment support
the use of calcium plus vitamin D supplements as an interven-
tion for fracture risk reduction in both community-dwelling
and institutionalized middle-aged to older adults.
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